Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07037277 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Study sites: 106 to 107
    v8
  2. Trial sites expanded: 89 → 106 locationsv7
  3. Study sites: 64 to 89v6
  4. Study sites: 28 to 64v5
  5. Study sites: 9 to 28v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 4 to 9
    • Start date: Jun 23, 2025 to Jun 2, 2025
    v3
  2. Study sites: 1 to 4
    • Start date changed from estimate of Jun 2025 to Jun 23, 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Trial Details
NCT Number NCT07037277
Lead Sponsor Atea Pharmaceuticals, Inc.
Conditions
(from sponsor)		 HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
Related terms Hepatitis C, Hepatitis C, Chronic
Enrollment 880 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov